MY126358A - Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs - Google Patents
Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgsInfo
- Publication number
- MY126358A MY126358A MYPI97001186A MYPI9701186A MY126358A MY 126358 A MY126358 A MY 126358A MY PI97001186 A MYPI97001186 A MY PI97001186A MY PI9701186 A MYPI9701186 A MY PI9701186A MY 126358 A MY126358 A MY 126358A
- Authority
- MY
- Malaysia
- Prior art keywords
- tpgs
- vitamin
- compositions
- water soluble
- tocopherol derivative
- Prior art date
Links
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003611 tocopherol derivatives Chemical class 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- KTOQRRDVVIDEAA-UHFFFAOYSA-N 2-methylpropane Chemical class [CH2]C(C)C KTOQRRDVVIDEAA-UHFFFAOYSA-N 0.000 abstract 1
- -1 TETRAHYDRO-3-FURANYL ESTER Chemical class 0.000 abstract 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical compound NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 abstract 1
- 239000004030 hiv protease inhibitor Substances 0.000 abstract 1
- 238000013160 medical therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1389396P | 1996-03-22 | 1996-03-22 | |
| GBGB9606372.2A GB9606372D0 (en) | 1996-03-26 | 1996-03-26 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY126358A true MY126358A (en) | 2006-09-29 |
Family
ID=26308992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI97001186A MY126358A (en) | 1996-03-22 | 1997-03-20 | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JP3117726B2 (pl) |
| AR (1) | AR006345A1 (pl) |
| BG (1) | BG64457B1 (pl) |
| CO (1) | CO4790151A1 (pl) |
| HU (1) | HU228026B1 (pl) |
| ID (1) | ID16781A (pl) |
| IL (1) | IL126185A (pl) |
| MY (1) | MY126358A (pl) |
| OA (1) | OA10880A (pl) |
| PL (1) | PL187919B1 (pl) |
| TW (1) | TW455491B (pl) |
| WO (1) | WO1997035587A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001523221A (ja) * | 1996-09-01 | 2001-11-20 | ファーモス コーポレイション | 親油性物質の促進された生物学的利用能のための固形共沈物 |
| AU8145198A (en) * | 1997-06-16 | 1999-01-04 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
| US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
| ES2140329B1 (es) * | 1997-12-04 | 2000-10-16 | Univ Granada | Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida. |
| GB9812189D0 (en) * | 1998-06-05 | 1998-08-05 | Glaxo Group Ltd | Methods and compositions for increasing penetration of HIV protease inhibitors |
| EP1354587A1 (en) * | 2000-12-22 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Medicinal compositions for oral use |
| AU2002350719A1 (en) * | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| JP2006518380A (ja) | 2003-01-31 | 2006-08-10 | スミスクライン・ビーチャム・コーポレイション | 固体分散体組成物 |
| WO2006036614A2 (en) * | 2004-09-24 | 2006-04-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer |
| CN101031284A (zh) * | 2004-09-30 | 2007-09-05 | 伊斯曼化学公司 | 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途 |
| EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
| ITRM20120331A1 (it) | 2012-07-12 | 2014-01-13 | Guidotti & C Spa Labor | Composizioni pediatriche orali liquide contenenti nepadutant. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992016501A1 (en) * | 1991-03-20 | 1992-10-01 | Vertex Pharmaceuticals Incorporated | Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease |
| DK0541168T3 (da) * | 1991-11-08 | 1998-05-11 | Merck & Co Inc | HIV-proteaseinhibitorer, som er egnede til behandling af AIDS |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| WO1994013629A1 (en) * | 1992-12-11 | 1994-06-23 | Vertex Pharmaceuticals Incorporated | Mannitol derivatives and their use as inhibitors of aspartyl protease |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| DE69334250D1 (de) * | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
| ATE179164T1 (de) * | 1993-01-15 | 1999-05-15 | Agouron Pharma | Hiv-proteaseinhibitoren |
| AU1046895A (en) * | 1993-11-05 | 1995-05-23 | Merck & Co., Inc. | New quinazolines as inhibitors of hiv reverse transcriptase |
| IL111584A0 (en) * | 1993-11-18 | 1995-01-24 | Merck & Co Inc | Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them |
| ES2174921T3 (es) * | 1993-12-15 | 2002-11-16 | Merck & Co Inc | Inhibidores de la proteasa del vih. |
| MX9603909A (es) * | 1994-03-07 | 1997-03-29 | Vertex Pharma | Derivados de sulfonamida como inhibidores de proteasa aspartilo. |
| GB9409778D0 (en) * | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
| US5527829A (en) * | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| EP0825849A1 (en) * | 1995-05-19 | 1998-03-04 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
-
1997
- 1997-03-20 MY MYPI97001186A patent/MY126358A/en unknown
- 1997-03-21 HU HU9901887A patent/HU228026B1/hu unknown
- 1997-03-21 WO PCT/EP1997/001438 patent/WO1997035587A1/en not_active Ceased
- 1997-03-21 AR ARP970101146A patent/AR006345A1/es active IP Right Grant
- 1997-03-21 TW TW086103607A patent/TW455491B/zh not_active IP Right Cessation
- 1997-03-21 CO CO97015457A patent/CO4790151A1/es unknown
- 1997-03-21 IL IL12618597A patent/IL126185A/xx not_active IP Right Cessation
- 1997-03-21 ID IDP970927A patent/ID16781A/id unknown
- 1997-03-21 PL PL32891697A patent/PL187919B1/pl unknown
- 1997-03-21 JP JP09534017A patent/JP3117726B2/ja not_active Expired - Lifetime
-
1998
- 1998-09-18 OA OA9800171A patent/OA10880A/en unknown
- 1998-10-12 BG BG102838A patent/BG64457B1/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU228026B1 (en) | 2012-08-28 |
| IL126185A (en) | 2003-05-29 |
| HUP9901887A3 (en) | 2000-02-28 |
| IL126185A0 (en) | 1999-05-09 |
| PL187919B1 (pl) | 2004-11-30 |
| CO4790151A1 (es) | 1999-05-31 |
| JP3117726B2 (ja) | 2000-12-18 |
| PL328916A1 (en) | 1999-03-01 |
| AR006345A1 (es) | 1999-08-25 |
| BG102838A (en) | 1999-09-30 |
| WO1997035587A1 (en) | 1997-10-02 |
| BG64457B1 (bg) | 2005-03-31 |
| ID16781A (id) | 1997-11-13 |
| TW455491B (en) | 2001-09-21 |
| HUP9901887A2 (hu) | 1999-12-28 |
| OA10880A (en) | 2001-10-11 |
| JP2000500504A (ja) | 2000-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6628496A (en) | Polyether block copolymer micellar compositions for targeting biological agents | |
| ECSP034883A (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen | |
| ATE533472T1 (de) | Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute | |
| ES2233931T3 (es) | Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos. | |
| IL114193A0 (en) | Ophthalmic pharmaceutical compositions | |
| PA8575701A1 (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
| MXPA05002814A (es) | Formulacion para agentes lipofilicos. | |
| NZ287857A (en) | Delivery of water insoluble active agents using tocopherol as emulsifier or solvent | |
| ES2156028T3 (es) | Composiciones que contienen tetrahidrolipstatina | |
| GEP20053473B (en) | High Potency Dihydroergotamine Compositions | |
| IL154888A (en) | Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid | |
| DE69520768D1 (de) | Pharmazeutische Zubereitungen, die Fluoxetin enthalten | |
| TR200001977T2 (tr) | Lipofilik glukokortikosteroit içeren miseller ihtiva eden bileşimler | |
| HUP0100539A2 (hu) | D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására | |
| BR0304298A (pt) | Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume | |
| HUP0004375A2 (hu) | Azelainsavat tartalmazó kompozíció | |
| AR006345A1 (es) | Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion. | |
| HU0001769D0 (en) | Use of lactophil composition in eye-drops containing pharmaceutical active ingredients | |
| MXPA03010628A (es) | Analogos de vitamina d. | |
| MXPA04005552A (es) | Analogos de vitamina d. | |
| PA8449301A1 (es) | Composiciones farmaceuticas | |
| CO4970832A1 (es) | Nuevas formulaciones y procesos para su fabricacion | |
| HRP20000781B1 (hr) | Šumeći pripravci | |
| DE69800804D1 (de) | Halbfeste pharmazeutische zubereitungen enthaltend dexketoprofen-trometamol | |
| EP1429723A4 (en) | TREATMENT EFFECTS OF EXCESSIVE REACTIVE OXYGEN SPECIES |